These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33156411)

  • 1. Erythropoietin-stimulating agent-resistant vitamin B
    Searcy K; Rainwater S; Jeroudi M; Baliga R
    Pediatr Nephrol; 2021 Feb; 36(2):473-476. PubMed ID: 33156411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effect of low-dose roxadustat combined with erythropoiesis-stimulating agent treatment for erythropoietin-resistant anemia in patients undergoing maintenance hemodialysis.
    Xu Q; Huang J; Liu Q; Wang X; Liu H; Song Y; Dou F; Lv S; Liu G
    Front Endocrinol (Lausanne); 2024; 15():1372150. PubMed ID: 39010898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.
    Santos EJF; Hortegal EV; Serra HO; Lages JS; Salgado-Filho N; Dos Santos AM
    Braz J Med Biol Res; 2018; 51(7):e7288. PubMed ID: 29742267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous Erythropoietin Receptor Activator for the Treatment of Chronic Dialysis Patients with Renal Anemia in Daily Clinical Practice in Poland: A Non-Interventional, Multi-Center, Pragmatic NAVIGO Trial.
    Nowicki M; Drożdż M; Wajda J; Klatko W; Segiet-Święcicka A
    Nephron; 2024; 148(2):104-112. PubMed ID: 37708860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
    Grabe DW
    Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
    Kobayashi H; Abe M; Okada K; Tei R; Maruyama N; Kikuchi F; Higuchi T; Soma M
    Nutrients; 2015 May; 7(5):3783-95. PubMed ID: 25988769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.
    Kuwahara M; Hasumi S; Mandai S; Tanaka T; Shikuma S; Akita W; Mori Y; Sasaki S
    Clin Exp Nephrol; 2014 Oct; 18(5):755-62. PubMed ID: 24317507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).
    Winkelmayer WC; Mitani AA; Goldstein BA; Brookhart MA; Chertow GM
    JAMA Intern Med; 2014 May; 174(5):699-707. PubMed ID: 24589911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease.
    Koury MJ; Agarwal R; Chertow GM; Eckardt KU; Fishbane S; Ganz T; Haase VH; Hanudel MR; Parfrey PS; Pergola PE; Roy-Chaudhury P; Tumlin JA; Anders R; Farag YMK; Luo W; Minga T; Solinsky C; Vargo DL; Winkelmayer WC
    Am J Hematol; 2022 Sep; 97(9):1178-1188. PubMed ID: 35751858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
    Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
    Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
    Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
    Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
    Pollak VE; Lorch JA; Shukla R; Satwah S
    BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5.
    Rianthavorn P; Boonyapapong P
    Pediatr Nephrol; 2013 Aug; 28(8):1261-6. PubMed ID: 23420502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
    Yoshida T; Hayashi M
    Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting erythropoiesis-stimulating agent (ESA) induces physiological erythropoiesis via improvement of iron availability.
    Masumoto M; Kuragano T; Takata C; Fukui R; Mihara Y; Okamoto R; Iwasaki T; Ookawa S; Aichi M; Yahiro M; Kida A; Nanami M
    Int Urol Nephrol; 2022 May; 54(5):1079-1084. PubMed ID: 34390438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
    Tsuruya K; Hayashi T; Yamamoto H; Hase H; Nishi S; Yamagata K; Nangaku M; Wada T; Uemura Y; Ohashi Y; Hirakata H;
    Clin Exp Nephrol; 2021 May; 25(5):456-466. PubMed ID: 33411115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.
    Nishio A; Chhatkuli BP; Ma JZ; Kalantari K
    Blood Purif; 2013; 36(1):29-36. PubMed ID: 23735569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.